Longitudinal Safety: An intentional gap? (policy)

The integration of longitudinal genetic and epigenetic studies into routine pharmaceutical safety evaluation is a critical and glaring knowledge gap that demands urgent attention within drug development and post-marketing surveillance pipelines. Despite the rapid advancement in genetic, epigenetic, and neuro- sciences enabling unprecedented molecular insight, current safety assessments largely overlook the cumulative and nuanced molecular impacts of chronic drug exposure, thereby potentially perpetuating unforeseen risks to patient safety and public health. This lack of progressive integration underscores profound ethical and scientific shortcomings that risk undermining both patient trust and optimal therapeutic outcomes.

Renewal of my commitments – 2025 edition

12:00m – Spoken audio, ‘reading’ of a 2007 outline with current day updates on the fly.

This is the first time I’m sharing out the active practice and I’m not sure that I will share all aspects as some are deeply private and personal in context.

That said, I will share the final recording OF them as a concept for any aid or support it may be to others. They only matter to me, of course, and that’s ok. But if you find help in them, be welcome to them and use as you like and prefer. Or, as a long lost friend once put it, “Appropriate as appropriate.”